Clinical Trials Browser

NCT02703623 2026-03-06

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

196 enrolled

Genitourinary

Prostatic Neoplasms

NCT04748042 2026-03-06

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

Phase 2 Active not recruiting

21 enrolled

Genitourinary

Prostatic Neoplasms

NCT03016741 2026-02-24

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Phase 4 Active not recruiting

100 enrolled

Genitourinary

Dementia, Prostatic Neoplasms, Cognitive Dysfunction, Prostatic Neoplasms, Castration-Resistant

NCT01786265 2026-02-20

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

Phase 2 Active not recruiting

310 enrolled

Genitourinary

Prostatic Neoplasms

NCT05137262 2026-02-18

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

Phase 2 Active not recruiting

12 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03902951 2026-02-05

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

Phase 2 Active not recruiting

28 enrolled

Genitourinary

Prostatic Neoplasms

NCT04267887 2026-01-20

Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer

Phase 2 Active not recruiting

7 enrolled

Genitourinary

Prostatic Neoplasms

NCT02949284 2026-01-07

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Phase 2 Active not recruiting

90 enrolled

Genitourinary

Stage II Prostate Adenocarcinoma

NCT05689021 2026-01-07

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

Phase 2 Active not recruiting

8 enrolled

Genitourinary

Prostatic Neoplasms

NCT02415621 2025-12-04

Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer

Phase EARLY_PHASE1 Active not recruiting

19 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT03511196 2025-12-04

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

Phase EARLY_PHASE1 Active not recruiting

17 enrolled

Genitourinary

Prostatic Neoplasms

NCT03436654 2025-11-28

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

Phase 2 Active not recruiting

102 enrolled

Genitourinary

Prostatic Neoplasms

NCT03012321 2025-10-21

Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

Phase 2 Active not recruiting

70 enrolled

Genitourinary

Prostatic Neoplasms

NCT03821792 2025-10-10

Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer

Phase 2 Active not recruiting

60 enrolled

Genitourinary

Prostatic Neoplasms

NCT04194554 2025-06-04

ASCLEPIuS

Phase 1/2 Active not recruiting

102 enrolled

Genitourinary

Prostatic Neoplasms

NCT02913196 2025-05-23

Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC

Phase 1 Active not recruiting

16 enrolled

Genitourinary

Prostate Cancer Metastatic

NCT01957436 2024-11-12

PEACE1

Phase 3 Active not recruiting

1,173 enrolled

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT03141671 2024-05-14

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

Phase 2 Active not recruiting

345 enrolled

Genitourinary

Prostatic Neoplasms

NCT06193993 2024-01-08

Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients

Phase 1 Active not recruiting

10 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms